Wednesday, July 8, 2026

Patent intelligence · US

US 7304080

Substituted 1,2,4-oxadiazoles, compositions and methods of use

granted A61KA61K31/4245A61K31/4439A61K31/454
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 1
Applicant portfolio 149
Patent details — US 7304080
Jurisdiction
US
Status
granted
Grant date
Dec 4, 2007
Expiration
Nov 29, 2027
Claims
19
CPC classes
A61K, A61K31/4245, A61K31/4439, A61K31/454
View on Google Patents ↗

Quick answer

US 7304080 (Substituted 1,2,4-oxadiazoles, compositions and methods of use) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Dec 4, 2007. Expires Nov 29, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61K, A61K31/4245, A61K31/4439, A61K31/454, A61K31/4545, A61K31/5377

More from PTC THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12398140

    Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Expires Aug 21, 2045

    granted
  2. US 12384789

    Compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Expires Aug 7, 2045

    granted
  3. US 12384797

    Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Expires Aug 7, 2045

    granted
  4. US 12281083

    2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof

    PTC THERAPEUTICS, INC. · Expires Apr 17, 2045

    granted
  5. US 12139499

    Heteroaryl compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Expires Nov 7, 2044

    granted
  6. US 12103926

    Compounds for treating huntington's disease

    PTC THERAPEUTICS, INC. · Expires Sep 26, 2044

    granted
  7. US 12023335

    Method for treating pancreatic cancer

    PTC THERAPEUTICS, INC. · Expires Jun 27, 2044

    granted
  8. US 11938101

    Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

    PTC THERAPEUTICS, INC. · Expires Mar 21, 2044

    granted

Frequently asked questions

What is US patent 7304080?

US 7304080 (Substituted 1,2,4-oxadiazoles, compositions and methods of use) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Dec 4, 2007. Expires Nov 29, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7304080?

PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.

When does US 7304080 expire?

Our index shows an expiration date of Nov 29, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.